| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT02503722 Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal… |
date change Primary completion pushed: 2026-06-05 -> 2027-02-28 |
| 2026-06-12 | NCT02503722 Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal… |
date change Completion pushed: 2026-06-05 -> 2027-02-28 |
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
Enrollment reduced: 403 -> 167 participants |
| 2026-06-12 | NCT05647122 First in Human Study of AZD9592 in Solid Tumors |
Trial sites reduced: 51 -> 46 locations |
| 2026-06-04 | NCT05642572 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has… |
date change Primary completion pushed: 2026-05-31 -> 2027-06-30 |
| 2026-06-04 | NCT05642572 Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has… |
date change Completion pushed: 2027-05-31 -> 2028-06-30 |
| 2026-05-27 | NCT07079475 Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have… |
Enrollment reduced: 200 -> 160 participants |
| 2026-05-27 | NCT07079475 Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have… |
Trial sites expanded: 7 -> 17 locations |
| 2026-05-23 | NCT07005102 A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab… |
Trial sites expanded: 48 -> 53 locations |
| 2026-05-14 | NCT07376382 A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With… |
Enrollment increased: 450 -> 680 participants |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07640789 A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in… | Phase 3 | Not Yet Recruiting |
| 2026-06-11 | NCT07642024 A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients… | Phase 2/3 | Not Yet Recruiting |
| 2026-06-03 | NCT07622186 A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer… | Phase 2 | Not Yet Recruiting |
| 2026-05-28 | NCT07612137 Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced… | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06838273 | A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line… | Non-small Cell Lung Cancer | Recruiting |
| NCT05624996 | Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for… | Locally Advanced Lung Non-Small Cell Carcinoma | Recruiting |
| NCT06350097 | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab… | Non-small Cell Lung Cancer | Recruiting |
| NCT06670196 | A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With… | Non-Small Cell Lung Cancer | Recruiting |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib… | Metastatic Non-small Cell Lung Cancer | Recruiting |
| NCT06486142 | EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study | Non-Small Cell Lung Cancer | Recruiting |
| NCT04181060 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With… | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recruiting |
| NCT02411448 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated… | Metastatic Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT02511106 | AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma… | Stage IB-IIIA Non-small Cell Lung Carcinoma | Active, Not Recruiting |
| NCT05261399 | Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants… | Carcinoma | Active, Not Recruiting |
| NCT05629234 | Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With… | Cancer | Active, Not Recruiting |
| NCT05120349 | A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT03521154 | A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients… | Non Small Cell Lung Cancer (Stage III) | Active, Not Recruiting |
| NCT07376382 | A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With… | NSCLC | Not Yet Recruiting |
| NCT04351555 | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| NCT04487080 | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally… | Carcinoma, Non-Small-Cell Lung | Active, Not Recruiting |
| NCT07640789 | A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in… | Non-small Cell Lung Cancer Stage III | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT07005102 | A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab… | Non-Squamous Non-Small Cell Lung Cancer | Recruiting |
| NCT07642024 | A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients… | Non-small Cell Lung Cancer | Not Yet Recruiting |
| Phase 2 | |||
| NCT07295821 | Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+… | Lung Cancer | Recruiting |
| NCT06741085 | A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung… | Non Small Cell Lung Cancer Metastatic | Recruiting |
| NCT07323641 | Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non… | Lung Non-Small Cell Carcinoma | Recruiting |
| NCT05528458 | Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage… | Lung Adenocarcinoma | Recruiting |
| NCT04591002 | Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive) | Lung Cancer | Recruiting |
| NCT06014827 | Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy… | Lung Non-Small Cell Carcinoma | Recruiting |